Lupin's share price rose today after the company announced the launch of Loteprednol Etabonate Ophthalmic Suspension, 0.5 per cent, in the US market.
With a strong offline base in Mumbai and Pune, Zeno Health plans to expand into Tier II and III cities, starting with Bihar, driven by increasing demand
Large-scale electronics manufacturing and pharmaceuticals cornered about 70 per cent of the total fiscal incentive disbursements in 2024-25 under the production-linked incentive (PLI) schemes, according to government data. The scheme was introduced in 2021 to support domestic manufacturing across 14 sectors with an outlay of Rs 1.97 lakh crore. In 2024-25, the government has disbursed a total of Rs 10,114 crore. PLI firms in the electronics sector received Rs 5,732 crore, while pharmaceutical drugs received Rs 2,328 crore, the data showed. In 2023-24, the disbursals stood at Rs 9,721 crore. The figures highlight the country's growing strength in these segments amid efforts to boost manufacturing and value-added exports. Besides these two, the other sectors that received these incentives in the last fiscal include bulk drugs (Rs 22 crore), Medical Devices (Rs 77 crore), Telecom (Rs 840 crore), Food Processing (Rs 448 crore), White Goods (Rs 210 crore), Automobiles (Rs 322 crore), .
IGI Therapeutics, a wholly owned subsidiary of Glenmark, has licensed its cancer and autoimmune drug ISB 2001 to AbbVie for an upfront payment of $700 million
Shilpa Medicare shares rose today after the company secured GMP certification from Saudi Arabia's SFDA for its Unit VI facility in Dabaspet, Bengaluru.
Emcure Pharma share price rose in trade after the company announced that United States Food and Drug Administration (USFDA) issued Form 483 with zero observations for its Sanand, Ahmedabad unit.
Lupin's share price rose in trade today after the company announced a licensing and supply agreement with Zentiva, k.s., for the commercialisation of its biosimilar Certolizumab Pegol.
Donald Trump threatens of a potential 200% tariff on pharma imports; can this derail the rally in pharma shares, which have gained up to 50% in 3 months. Here's what the technical charts suggest.
Sun Pharma expects global pricing strain due to policy shifts, as FY25 US sales rise 5.8% despite compliance challenges; specialty business lifts overall growth
Alembic Pharmaceuticals share price rose after the company announced that its wholly-owned subsidiary, Alembic Pharmaceuticals Inc., has acquired Utility Therapeutics Ltd. for approximately $12 mn
AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi (Durvalumab) in India.
Despite steep premium and short-term earnings dilution, analysts expect Torrent Pharma's acquisition of JB Chemicals to be value accretive in the medium term
Torrent Pharmaceuticals has signed a definitive agreement to acquire a controlling stake in JB Chemicals and Pharmaceuticals (JBCP) at a fully diluted equity valuation of ₹25,689 crore.
Alembic Pharmaceuticals share surged after the company received final approval from the USFDA for its ANDA for Doxorubicin Hydrochloride Liposome Injection in two dosage strength.
Torrent Pharma will acquire KKR's 46.39% stake in JB Pharma followed by open offer and merger, strengthening chronic segment and CDMO footprint in India and abroad
Torrent Pharma is negotiating to acquire JB Chemicals from KKR in a deal that may trigger an open offer, strengthening its position in the domestic pharma market
Yesafili is the first Eylea biosimilar approved in Canada and Biocon Biologics' 10th commercialised biosimilar, with launch scheduled for July 4 across the country
Torrent Pharma share price rose after JPMorgan reportedly upgraded the company to 'Overweight'. The brokerage also hiked the target price to ₹3,800, from ₹3,650 earlier.
Eli Lilly's once-weekly KwikPen format for Mounjaro has been approved in India, offering an easier delivery system for type 2 diabetes and chronic weight management
Global bio-pharmaceutical company AstraZeneca has established its state-of-the-art Global Hub in Bengaluru investing Rs 166 crore to focus on development of AI-powered healthcare solutions, a top official said on Thursday. This marks the second major investment by AstraZeneca in July 2024 after it announced expansion of its Global Innovation and Technology Centre in Chennai with an outlay of Rs 250 crore. The new facility in Bengaluru is designed to accommodate nearly 1,300 employees including 400 new jobs. It will support the company's capabilities in AI-powered innovation across Research and Development, global business services, Information Technology and digital health operations, among others. The Global Hub in Bengaluru is dedicated to Research and Development, Global Business Services, Information Technology while the Global Innovation and Technology Centre in Chennai serves as a strategic hub for IT, Global Business Services. Following the expansion of the facility, the ...